Ipamorelin research and evidence overview

Around 50 PubMed-indexed papers mention ipamorelin, and they divide cleanly. The animal literature is consistent and reproducible: ipamorelin activates the ghrelin receptor, releases GH, and does so without disturbing other pituitary hormones. The human literature is two studies — a pharmacokinetic dose-escalation in 48 healthy men and a phase 2 efficacy trial in 114 bowel-resection patients — plus one 320-patient study whose results were never made public. The trial that tested a clinical outcome was negative, and development stopped there.

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) came out of a Novo Nordisk chemistry program searching among compounds that lacked the central Ala-Trp dipeptide of GHRP-1. In isolated rat pituitary cells it released GH with potency close to GHRP-6 (EC50 1.3 vs 2.2 nmol/L, Emax 85% vs 100%), and the same effect appeared in anesthetized rats and conscious swine (Raun et al., Eur J Endocrinol 1998).

The result that made the paper notable was negative: ipamorelin did not release ACTH or cortisol above the levels seen after GHRH stimulation, even at doses more than 200 times the GH-releasing dose, and did not move FSH, LH, prolactin, or TSH. The authors described it as the first GHRP-receptor agonist with GH selectivity comparable to GHRH itself. Every "selective secretagogue" claim made about ipamorelin since traces back to this single paper.

The rodent literature that followed pursued two themes.

• Bone and growth. Fifteen days of subcutaneous dosing (18, 90, or 450 µg/day) raised longitudinal bone growth in adult female rats from 42 to 52 µm/day dose-dependently, with a pronounced effect on body weight — but no change in total IGF-1, IGF binding proteins, or bone formation and resorption markers (Johansen et al., Growth Horm IGF Res 1999). Twelve weeks of continuous infusion increased bone mineral content, but analysis showed the gain came from increased bone dimensions rather than denser bone; volumetric density and mineral concentration were unchanged (Svensson et al., J Endocrinol 2000).

• Gastrointestinal motility. In a rat model of postoperative ileus, a single intravenous dose shortened time to first bowel movement but changed nothing else; repeated dosing (0.1 or 1 mg/kg, four doses daily) significantly increased cumulative fecal output, food intake, and body-weight gain. The authors concluded postsurgical infusions "may ameliorate the symptoms in patients" (Venkova et al., J Pharmacol Exp Ther 2009).

This second theme carried ipamorelin into the clinic — a reminder that a well-designed animal model can support a hypothesis humans then decline to confirm.

Pharmacokinetics (1999). Five escalating 15-minute intravenous infusions (4.21–140.45 nmol/kg), six healthy men per dose level, plus placebo. Kinetics were dose-proportional: terminal half-life about 2 hours, clearance 0.078 L/h/kg, steady-state volume of distribution 0.22 L/kg. GH rose to a sharp peak around 0.67 hours and declined to very low concentrations by 6 hours at all doses. Between-subject variability was larger in the pharmacodynamic response than in the kinetics (Gobburu et al., Pharm Res 1999).

Phase 2 efficacy (2014). A prospective, multi-center, randomized, double-blind, placebo-controlled trial enrolled 117 adults undergoing small or large bowel resection; 114 received 0.03 mg/kg intravenous ipamorelin (n=56) or placebo (n=58) twice daily from postoperative day 1 to day 7 or discharge. The primary endpoint — time to tolerating a standardized solid meal without nausea or vomiting — was 25.3 hours vs 32.6 hours, p = 0.15. The authors reported no significant differences in the key or secondary efficacy analyses (Beck et al., Int J Colorectal Dis 2014).

The study nobody has seen. A 320-patient, four-arm dose-finding study (0.03 mg/kg twice daily, 0.06 mg/kg twice daily, 0.06 mg/kg three times daily, or placebo) ran from 2011 to 2014 (NCT01280344). It is listed as completed; no results were posted and no peer-reviewed report appears in PubMed. That study is the largest human exposure on record, and the silence around it is itself part of the evidence base.

In 2024 the FDA evaluated ipamorelin after compounding pharmacies nominated it for the list of bulk substances usable in compounded medicines. The review concluded that evidence of effectiveness for growth hormone deficiency or postoperative ileus is limited for any route, that no data support the proposed subcutaneous route for either condition, and that professional guidelines do not mention the substance. It also noted that non-clinical toxicity studies were "too limited in scope and duration" to inform clinical use, and that no published study addresses carcinogenic potential (FDA briefing document, August 2024).

On 29 October 2024 the Pharmacy Compounding Advisory Committee voted 0 in favour, 12 against, 1 abstention on ipamorelin (free base), and the same on ipamorelin acetate, "agreeing that there was a lack of information supporting safety and efficacy" (PCAC final summary minutes).

Three habits help. First, watch the species: the selectivity, bone, and motility findings are all rodent or swine data, and the human record contains no multi-week hormone panel. Second, separate hormone endpoints from outcome endpoints — ipamorelin passes the first reliably and has been tested against the second exactly once, unsuccessfully. Third, note the route: every human number here came from an intravenous infusion, while essentially all present-day use is subcutaneous.

For the compound overview and FAQ, see the ipamorelin detail page; for the claims made on its behalf, see benefits.